| Analysts were expecting Biovail Corporation (BVF) [Chart - News - Analysis] to report earnings of $0.40 for last quarter, but BVF beat expectations with actual earnings of $0.61---21 cents above the consensus estimate. If you compare last quarter's earnings to the $0.32 the company made per share during the same quarter a year ago, you can see that BVF’s earnings are up this year. Check this out (it's free!): Stocks You Should Be Watching Right Now; How to Make Good Picks
| | | | | |
-
Essential Reading for Traders
-
| | |
| | | | | | | | Also, if you compare BVF's 7.50% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 14.05% for the Drug Delivery industry as a whole during that same time frame, you can see that analysts expect BVF to underperform the industry in the future---which is a bad sign for the stock. Drilling down a little deeper into the Drug Delivery industry, you can see how analysts believe BVF will stack up against some of the other stocks in the industry, like Nektar Therapeutics (NKTR) [Chart - News - Analysis] and Flamel Technologies SA (FLML) [Chart - News - Analysis], in the future. Analysts believe NKTR's earnings are going to grow at a rate of 16.00% while FLML's earnings are going to grow at a rate of 0.00%. Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements. - Earnings Season is Here - Find Out How to Trade It - Using Options to Trade Earnings - Understanding Stock Analyst Research and Recommendations More...
Keep up with us:
| 
